Text this: Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments

 _    _      ___       _____     ___     _    _   
| || | ||   / _ \\    / ___//   / _ \\  | \  / || 
| || | ||  | / \ ||   \___ \\  | / \ || |  \/  || 
| \\_/ ||  | \_/ ||   /    //  | \_/ || | .  . || 
 \____//    \___//   /____//    \___//  |_|\/|_|| 
  `---`     `---`   `-----`     `---`   `-`  `-`